 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||| RG6123 / Roche
Trial termination, Metastases: A Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors (clinicaltrials.gov) - Sep 3, 2020
P1, N=26, Terminated, Sponsor: Hoffmann-La Roche
Completed --> Terminated; Study terminated due to change in benefit-risk ratio, driven by high incidence GI toxicity in absence of clinically significant anti-tumor efficacy.
- ||| $RHHBY discontinuations: RG6109 undiscl ADC; RG6123 anti-CEA MAb; RG6146 bromodomain inh; RG6148 undisclosed (Her2+ breast cancer); RG7625 cathepsin S inh (Twitter) - Oct 16, 2019
- | RG6123 / Roche
Trial completion, Metastases: A Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors (clinicaltrials.gov) - Oct 7, 2019
P1, N=26, Completed, Sponsor: Hoffmann-La Roche
Completed --> Terminated; Study terminated due to change in benefit-risk ratio, driven by high incidence GI toxicity in absence of clinically significant anti-tumor efficacy. Terminated --> Completed
- | RG6123 / Roche
Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Metastases: A Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors (clinicaltrials.gov) - Aug 8, 2019
P1, N=26, Terminated, Sponsor: Hoffmann-La Roche
Terminated --> Completed N=150 --> 26 | Trial completion date: Dec 2020 --> Jul 2019 | Recruiting --> Terminated | Trial primary completion date: Dec 2020 --> Jul 2019; Study terminated due to change in benefit-risk ratio, driven by high incidence GI toxicity in absence of clinically significant anti-tumor efficacy.
- | RG6123 / Roche
Trial completion date, Metastases: A Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors (clinicaltrials.gov) - Jun 27, 2019
P1, N=150, Recruiting, Sponsor: Hoffmann-La Roche
N=150 --> 26 | Trial completion date: Dec 2020 --> Jul 2019 | Recruiting --> Terminated | Trial primary completion date: Dec 2020 --> Jul 2019; Study terminated due to change in benefit-risk ratio, driven by high incidence GI toxicity in absence of clinically significant anti-tumor efficacy. Trial completion date: Jun 2021 --> Dec 2020
- || RG6123 / Roche
Trial completion date, Trial primary completion date, Metastases: A Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors (clinicaltrials.gov) - Mar 21, 2019
P1, N=150, Recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: Jun 2021 --> Dec 2020 Trial completion date: Apr 2020 --> Jun 2021 | Trial primary completion date: Oct 2019 --> Dec 2020
- ||| RG6123 / Roche
Enrollment open, Metastases: A Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors (clinicaltrials.gov) - Jul 3, 2018
P1, N=125, Recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: Apr 2020 --> Jun 2021 | Trial primary completion date: Oct 2019 --> Dec 2020 Not yet recruiting --> Recruiting
- ||| RG6123 / Roche
New P1 trial, Metastases: A Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors (clinicaltrials.gov) - Jun 3, 2018
P1, N=125, Not yet recruiting, Sponsor: Hoffmann-La Roche